Pfizer has appointed James List, a former executive from Johnson & Johnson, as its new Chief Internal Medicine Officer to enhance the company’s efforts in obesity drug development. List has a strong background in the pharmaceutical industry, with over 20 years of experience in various leadership roles. He has a deep understanding of the industry, having spent 15 years at Johnson & Johnson, most recently serving as the company’s Vice President, Worldwide Oncology and Inflammation.
As the new Chief Internal Medicine Officer at Pfizer, List will be responsible for leading the company’s efforts in developing and commercializing innovative treatments for a range of diseases, including obesity, which is a significant unmet medical need. Under the leadership of List, Pfizer will delve deeper into using innovative technologies and approaches to develop new treatments for various diseases.
List’s appointment at Pfizer is seen as a significant move to strengthen the company’s capabilities in internal medicine, which is a critical area of focus given the increasing prevalence of chronic diseases worldwide. The move is also expected to boost Pfizer’s research and development efforts, as well as its pipeline of innovative treatments.